ClinicalTrials.gg
Active, not recruitingNCT06969352VICTORIAUpdated Jul 21, 2026

A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)

An interventional study of Vorasidenib in Gliomas, sponsored by Servier (Tianjin) Pharmaceutical Co. LTD.. Active, not recruiting at 3 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Servier (Tianjin) Pharmaceutical Co. LTD. · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 162 studies in Glioma with a site in China — 70 open to participants now, 82 under way, 3 of them phase 3. Glioma · China.

Enrollment
34th of 112
62 · median 40
Started
2025
with 15 others
No phase
36 of 162
14 open now
Primary completion
2028-04
later than 68 of 81 live
Registered
133rd of 162
by date

Among the 162 studies in Glioma with a site in China, this one is the 34th largest by enrollment of the 112 interventional ones that give a count, is one of 16 that started in 2025, is one of 36 with no phase, reaches primary completion later than 68 of the 81 other live ones, and was the 133rd registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

70 of the 162 studies in Glioma with a site in China are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 267 Glioma studies recruiting now, 164 (61%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Glioma with a site in China, or all of them as a file.
02

Study summary

The goal of this Study is to evaluate the effectiveness and safety of Vorasidenib in Patients with Isocitrate dehydrogenase IDH1/2 mutant Grade 2 astrocytoma or oligodendroglioma, primary purposeis to evaluate the efficectiveness of Vorasidenib in glioma patients treated in routine clinical practice in In China, patients aged 12 and above with grade II or higher astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations. The main question it aims to answer is:

if this trend is consistent with the efficacy observed in the INDIGO study, and there is not any new safety signal compared to previous research data? Researchers will compare to no treatment. Participants is not mandatory for a formal visit as it is a real-word study.However, due to the fact that patients will be treated with new drugs and need to collect data on major efficacy, regular visits should be performed in routine clinical practice.

This study is a multicenter, retrospective-and prospective real-world study, There are treatment group (Vorasidenib) and external control group (untreated after surgery).

03

Conditions studied

  • Gliomas

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion and exclusion criteria for treatment group

Patients will be included if they meet all the following criteria:

  1. Patients (female and male) aged ≥ 12 years at enrolment.
  2. Patients with tissue-confirmed diagnoses of Grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutation
  3. Have undergone at least one prior glioma surgery (, subtotal resection, or complete resection).
  4. Patients with evaluable disease based on the most recent MRI in the opinion of the treating physician. A measurable non-enhanced lesion is defined as at least one target lesion with dimensions of ≥1 cm × ≥1 cm (in two dimensions). Confirmed by a centralized IRC as minimal, non-nodular, and non-measurable enhancement.
  5. The PI evaluates based on the Vorasidenib label and patients is willing plan to receive Vorasidenib
  6. Be able to understand and provide written if the patient is 18 years or older, or if the patient is a minor (12 years or older and under 18 years), both the patient and their legal representative must sign the informed consent.

Patients who meet at least one of the following exclusion criteria will not be included in the study:

  1. Patients who received radiotherapy, chemotherapy or other IDH inhibitor for Glioma before enrolment.
  2. Patients with any contrindications to Vorasidenib

Inclusion and exclusion criteria for the external control group

Patients will be included if they meet all the following criteria:

  1. Patients (female and male) aged ≥ 12 years at the index date.
  2. Patients with tissue-confirmed diagnoses of Grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutation
  3. Have undergone at least one prior glioma surgery (biopsy, subtotal resection, or complete resection) before the index date.
  4. Since the index date, the patient must have undergone at least two magnetic resonance imaging (MRI) scans with an interval of at least 6 months (±30 days), showing measurable or evaluable non-enhancing lesions. Measurable non-enhancing lesions are defined as at least one target lesion that is ≥1 cm × ≥1 cm (two-dimensional). These lesions must be centrally confirmed by the IRC (Independent Review Committee) as small, non-nodular, and nonmeasurable enhancing lesions.

6) Must have at least 6 months (±30 days) follow-up historical data since the index date without any treatment in this period.

Patients who meet at least one of the following exclusion criteria will not be included in the study:

1) Patients who received radiotherapy, chemotherapy or other IDH inhibitors for Glioma before the index date.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    treatment group(Vorasidenib)

    As a real-world study, in principle, a formal visit is not mandatory. However, due to the fact that patients will be treated with new drugs and need to collect data on major efficacy, regular visits should be performed in routine clinical practice.

    Drug: Vorasidenib

  • No intervention
    external control group (untreated after surgery)

    Eligible patients are those who have MRI data available for analysis after glioma surgery (including biopsy, subtotal resection, or total resection) and at least one additional MRI scan available for analysis within the following 6 months after the index data During this period, the eligible patients who have not undergone radiotherapy or chemotherapy after resection will be included in the external control arm.

Interventions

  • Treatment group: recommended dosage in adults and paediatric patients 12 years of age and older: * For patients weighing at least 40 kg: 40 mg, orally, once daily. * For patients weighing less than 40 kg: 20 mg, orally, once daily.

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint

    TGR at 6 months after the index date\*. TGR is defined as percentage change in tumour volume from baseline.

    Time frame: at 6 months after the index date

Secondary outcomes

  1. Secondary efficacy endpoint

    TTNI, TTNI is defined as the time from enrolment to the initiation of the first subsequent anticancer therapy or death due to any causes whichever occurs earlier.

    Time frame: 30 months after the index date of the last required sample patient

  2. Secondary efficacy endpoint

    rwPFS, defined as the time from enrolment to physician-documented disease progression or date of death due to any cause, whichever occurs earlier, evaluated according to the modified RANO-LGG.

    Time frame: 30 months after the index date of the last required sample patient

  3. Secondary efficacy endpoint

    TGR every 6 months after the index date, defined as the percentage change in tumor volume every 6 months after the index date in the Vorasidenib treatment group, as assessed per IRC.

    Time frame: 30 months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Apr 2028, 31 months after the start.

Of 142 interventional studies with no phase under Glioma, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 114. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 13, 2025
StartActual
Sep 2, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06969352
Lead sponsor
Servier (Tianjin) Pharmaceutical Co. LTD.
Collaborators
Institut de Recherches Internationales Servier (I.R.I.S.), Hainan Boyan Medical Research Co. Ltd., Fantastic Bioimaging Co., Ltd., Clinical TrialService (Guangzhou) Co.,Ltd
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Sep 2, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jul 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorasidenib

Start the discussion